Parmi les sujets non traités, la réduction médiane de cholestérol-LDL nécessaire pour atteindre l'objectif, variait de 6,6 % (sujets les moins à risque) à 36,0 % (haut risque). Lorsque le risque était défini selon les critères européens, la majorité des participants n'atteignait pas l'objectif, qu'il y ait ou non prise d'un traitement hypolipémiant.
Background
Current guidelines for the prevention and treatment of cardiovascular disease emphasize the importance of treating multiple risk factors, including dyslipidaemia and hypertension, depending on the patient's overall level of risk [1] [2] [3] . This approach is also recommended in the most recent evidence-based review on dyslipidaemia management from the French health agency (Haute Autorité de santé) [4] . The potential impact of lipid-lowering therapy on the prevalence of dyslipidaemia in France has been highlighted by epidemiological data from the MONItoring of trends and determinants in CArdiovascular disease (MONICA) project, which were obtained in 1996-1997, and the MONA LISA (MOnitoring NAtionaL du rISque Artériel) survey, which was conducted between 2006 and 2007 [5] . These studies showed significant decreases in low-density lipoprotein (LDL)-cholesterol concentrations and dyslipidaemias over a 10-year period, concurrent with the increasing use of lipidlowering therapy, particularly statins [5] .
Despite the existence of numerous national and international guidelines for the management of dyslipidaemia, several studies have shown that management is often suboptimal in Europe [6, 7] . Besides, prevalence of cardiovascular risk factors is still substantially elevated in France [5, [8] [9] [10] [11] . The aim of this analysis from the MONA LISA study was to investigate, in the French general population, the attainment of LDL-cholesterol targets in subjects at various levels of cardiovascular risk, as defined in the most recent French [4] and European [2] guidelines.
Methods
Details of the MONA LISA survey have been published previously [5, [8] [9] [10] [11] . Participants aged 35 to 74 years were recruited between 2006 and 2007 from the general population in three regions of France: the Lille urban community in Northern France, the Bas-Rhin department in Eastern France and the Haute-Garonne department in South West France. The participants were selected randomly from electoral rolls after stratification by town size, sex and age, in order to achieve a sample size of 200 of each sex in each age group (35-44 years, 45-54 years, 55-64 years, 65-74 years) and each region. In accordance with French law, the study protocol was approved by the appropriate independent ethics committee and written informed consent was obtained from all participants.
Included subjects responded to a standardized questionnaire, covering demographic variables, socioeconomic status, medical history and drug intake, and underwent a standardized physical examination. Blood pressure was measured twice, at rest, with a standard sphygmomanometer (OMRON ® 705IT). A 20 mL blood sample was collected into a disodium ethylene-diamine-tetraacetic acid tube after an overnight fast (at least 10 h) and plasma was separated by centrifugation within 4 h. Cholesterol and triglyceride concentrations were measured by enzymatic assays (Olympus, Melville, NY, USA), and glucose was measured by the standard glucose hexokinase assay (DuPont Dimension, Brussels, Belgium). High-density lipoprotein (HDL)-cholesterol was assessed after sodium phosphotungstate/magnesium chloride precipitation (Olympus); LDL-cholesterol was determined by the Friedewald equation if triglyceride concentrations were less than 4.6 mmol/L (4 g/L). All biological measurements were performed in a core laboratory (Institut Pasteur de Lille).
Assessment of cardiovascular risk
For each participant, the presence of cardiovascular risk factors (family history of premature coronary heart disease [CHD], hypertension, smoking, dyslipidaemia or diabetes) was recorded and the global cardiovascular risk was calculated using established scoring systems [2] [3] [4] 12, 13] . A family history of premature CHD was defined as the occurrence of a myocardial infarction in the participant's father before the age of 55 years or in the participant's mother before 65 years. Smoking referred to current smoking (any type of smoking: cigarettes, cigars, pipe) or past smoking stopped within the previous 3 years. Hypertension was defined as a resting blood pressure of greater or equal to 140/90 mmHg (mean of two measurements) or greater or equal to 130/80 mmHg among people with diabetes or an estimated glomerular filtration rate (eGRF) less than 60 mL/min/1.73 m 2 (evaluated by the Modification of Diet in Renal Disease formula) or the use of antihypertensive medications. Hypercholesterolaemia was defined as an LDL-cholesterol concentration greater or equal to 4.1 mmol/L (1.6 g/L) or the use of lipid-lowering medication with triglyceride concentration less than 1.7 mmol/L (1.5 g/L); hypertriglyceridaemia or combined dyslipidaemia were defined as triglyceride concentration greater or equal to 1.70 mmol/L (1.5 g/L) and low HDL-cholesterol was defined as a concentration less than 1 mmol/L (0.4 g/L). Diabetes was defined as a fasting blood glucose concentration greater or equal to 7 mmol/L (1.26 g/L) or the use of hypoglycaemic drug treatment.
The 10-year risk of CHD (corresponding to the probability of a given subject developing CHD in the next 10 years) was calculated using the Framingham algorithm [13] and the 10-year risk of fatal cardiovascular disease (death caused by any arterial disease, including coronary, cerebrovascular and other artery diseases, and sudden death) was estimated using the Systematic Coronary Risk Evaluation (SCORE) system [12] .
The level of risk was also scored according to the French guidelines, based on the number of risk factors present [4] . These risk factors were: age (≥ 50 years in men and ≥ 60 years in women), family history of premature CHD, current or past smoking as defined above, hypertension, diabetes and low HDL-cholesterol. The total number of risk factors was reduced by one if the HDL-cholesterol concentration was greater than 1.6 mmol/L (0.6 g/L). Subjects were considered to be at high risk if they had documented cardiovascular disease (coronary heart disease, cerebrovascular disease, aortic aneurysm or atherosclerosis affecting the aorta or leg arteries), diabetes and eGFR less than 60 mL/min/1.73 m 2 or diabetes with at least two other risk factors or a 10-year risk of CHD of at least 20%.
The level of risk was also estimated according to the 2012 guidelines for cardiovascular prevention from the European Society of Cardiology (ESC) [2] . Subjects were considered to be at low risk if their SCORE rating was less than 1% (corresponding to a 10-year probability of cardiovascular mortality of less than 1%), and they were categorized at moderate risk if SCORE was greater or equal to 1% and less than 5%. Subjects with markedly elevated single risk factors (arterial blood pressure greater or equal to 180/110 mmHg or LDL-cholesterol greater or equal to 5.7 mmol/L [2.2 g/L]) were categorized at high risk, as well as those with diabetes (without associated cardiovascular risk factors), moderate chronic kidney disease (eGFR ranging between 30 and 59 mL/min/1.73 m 2 ), or a SCORE rating greater or equal to 5% and less than 10%. Subjects at very high risk were those with documented cardiovascular disease (as detailed above), severe chronic kidney disease (eGFR less than 30 mL/min/1.73 m 2 ), diabetes with one or more associated cardiovascular risk factor(s), diabetes with eGFR less than 60 mL/min/1.73 m 2 or subjects with a SCORE rating greater or equal to 10%.
Targets for LDL-cholesterol according to levels of cardiovascular risk
According to French guidelines [4] , LDL-cholesterol should be less than 5.7 mmol/L (2.2 g/L) in subjects with no associated risk factors, less than 4.9 mmol/L (1.9 g/L), 4.1 mmol/L (1.6 g/L), and 3.4 mmol/L (1.3 g/L) in those with one, two and three associated risk factors, respectively, and less than 2.6 mmol/L (1.0 g/L) in high-risk subjects. According to the ESC guidelines [2] , targets for LDL-cholesterol are 3 mmol/L (1.15 g/L) in people at low or moderate risk, 2.6 mmol/L (1.0 g/L) in those at high risk and 1.8 mmol/L (0.7 g/L) in subjects at very high-risk.
Statistical analysis
Continuous variables were summarized as mean ± standard deviation or median (interquartile range) for non-normally distributed variables. Categorical variables were presented as absolute numbers, with percentages and 95% confidence intervals. The percentage of subjects in whom LDL-cholesterol targets were not achieved was estimated in the overall sample and subsequently in participants who were and were not receiving lipid-lowering therapy. In the overall sample, this percentage was also estimated after direct standardization, using the 2009 French population to provide a reference distribution for age and sex. The percentage reduction required to meet the LDL-cholesterol target in a given subject was calculated as:
All analyses were performed with SAS ® software (SAS Institute, Cary, NC, USA), except for standardized estimates, which were computed with STATA ® software (STATA Corporation, College Station, TX, USA).
Results

Study population
Participation rates in the MONA LISA study were 50% for men and 51% for women, resulting in a total of 4769 participants aged 35 to 74 years, of whom 4609 were included in the present analysis. Overall, 160 participants (3.4%) were excluded: LDL-cholesterol could not be estimated in 56 subjects because triglyceride concentrations were greater or equal to 4.6 mmol/L (4 g/L), 26 subjects provided a nonfasting blood sample and data on cardiovascular risk factors were missing in 78 subjects.
Demographic characteristics, cardiovascular risk factors and global levels of cardiovascular risk for the included participants are summarized in Table 1 . Approximately 50% of the participants were hypertensive and 53.6% had hypercholesterolaemia, hypertriglyceridaemia or combined dyslipidaemia. The mean LDL-cholesterol in the overall population was 3.63 ± 0.91 mmol/L (1.41 ± 0.35 g/L). In total, 946 subjects were receiving treatment with lipid-lowering drugs; of these, 78.4% received a statin, 19.1% a fibrate and 2.5% were treated with another lipid-lowering therapy. A total of 1615 subjects (35.0%) had no associated cardiovascular risk factors (i.e. no risk factors except possibly high LDL-cholesterol, as defined in the French guidelines [4] ), but 178 (3.9%) had three or more associated risk factors and 808 (17.5%) were considered to be at high risk. Similarly, when risk was assessed according to the ESC guidelines [2] , 14.1% and 11.3% were considered to be at high or very high risk, respectively. The median 10-year risks of CHD and fatal cardiovascular disease were 7.5% and 0.60%, respectively.
Attainment of LDL-cholesterol goals
The proportion of participants not attaining the recommended LDL-cholesterol target concentration varied according to the level of cardiovascular risk defined in the French guidelines (Table 2) . Among participants with no associated cardiovascular risk factors, almost all had LDLcholesterol concentrations below the recommended target concentration (< 5.7 mmol/L, 2.2 g/L). However, the proportion of participants in whom targets were not achieved increased progressively with the number of risk factors present. Among the subjects at highest risk, the recommended LDL-cholesterol target (< 2.6 mmol/L, 1.0 g/L), was not achieved in 82.5% (92.3% of those who were not receiving lipid-lowering therapy and 70.8% of those who were). Among these high-risk subjects, analyses were stratified to distinguish between people in secondary cardiovascular prevention and those at high risk but in primary prevention (i.e. subjects with diabetes and eGFR less than 60 mL/min/1.73 m 2 , subjects with diabetes and at least two other risk factors or subjects with a 10-year risk of CHD of greater or equal to 20% but without documented cardiovascular disease). The proportion of participants not reaching LDL-cholesterol target was 87.1% in high-risk primary prevention subjects but was significantly lower (68.7%) in secondary prevention subjects (P less than 0.0001 for 2 test). When participants' cardiovascular risk was classified according to the ESC guidelines [2] , the majority of participants did not reach the LDL-cholesterol targets recommended in those guidelines, irrespective of their level of risk or lipid-lowering therapy. Approximately three-quarters of participants at lowest risk did not reach the recommended LDL-cholesterol target of less than 3 mmol/L (1.15 g/L), while 95.8% of those at very high risk did not reach the more stringent target of less than 1.8 mmol/L (0.7 g/L) ( Table 2) . Tables 3 and 4 show the reductions in LDL-cholesterol needed to reach the recommended LDL-cholesterol targets in those participants in whom these targets were not achieved. Among the participants who were not receiving lipid-lowering therapy, the mean LDL-cholesterol concentrations ranged from 6.23 ± 0.65 mmol/L (2.41 ± 0.25 g/L) in participants with no associated risk factors according to the French guidelines to 4.02 ± 0.47 mmol/L (1.56 ± 0.18 g/L) and 4.06 ± 0.82 mmol/L (1.57 ± 0.32 g/L) in those at the highest levels of risk. The median percentage reduction in LDL-cholesterol needed to reach the targets recommended in the French guidelines ranged from 6.6% in the lowest-risk groups to 36.0% in subjects with the highest risk ( Table 3) . The great majority of participants with three associated risk factors or fewer required reductions of less than 30% to reach their LDL-cholesterol target, whereas 52.7% of the participants at high risk required reductions of 30 to 49% and 8.8% required reductions of greater or equal to 50% (Table 3) .
Mean LDL-cholesterol concentrations ranged from 3.69 to 4.27 mmol/L (1.43 to 1.65 g/L) in untreated participants at all levels of risk according to the ESC guidelines and the median LDL-cholesterol reductions needed to reach the targets recommended in these guidelines increased from 21.7% in participants at low risk to 50.2% in those at very high risk. All participants at low or moderate risk required LDLcholesterol reductions of less than 50% to reach their target, whereas 50.2% of participants at very high risk required reductions of greater or equal to 50% (Table 3) .
Similar trends were seen in participants who did not reach their LDL-cholesterol target despite receiving lipid-lowering therapy (Table 4) . In these participants, LDL-cholesterol concentrations were generally lowest in participants at the highest levels of risk, whether assessed according to the French or the ESC guidelines. Among participants with 0-3 associated risk factors according to the French guidelines, a very large majority required reductions of less than 30% in LDL-cholesterol to reach their recommended targets. The required reduction was larger among high-risk subjects since almost one third needed a 30 to 49% reduction. When ESC criteria were applied, 48.8% of participants at very high risk needed a 30 to 49% reduction in LDL-cholesterol and 19.0% a reduction of greater or equal to 50% (Table 4) .
Discussion
Recent years have seen favourable trends towards decreases in total and LDL-cholesterol concentrations in France [5] and other European countries [14, 15] and in the USA [16, 17] . Despite these encouraging trends, however, the results of the present study show that dyslipidaemia remains poorly controlled in France. A high proportion of primary prevention candidates and an even higher proportion of people at high cardiovascular risk do not meet either the LDLcholesterol targets recommended in the French guidelines or the more stringent targets recommended in the ESC guidelines. This study formed part of the MONICA project, which has been monitoring cardiovascular risk factors in France and other European countries since 1985 [5, 18] . Most centres participating in this project have subsequently stopped collecting data because of financial constraints, so there are few cross-sectional data from other countries that can be compared with the results of the present study. Recent data from the US Centers for Disease Control (CDC) indicate that, although more than two thirds of American adults had undergone cholesterol screening within the previous 5 years, more than 13% had elevated total cholesterol in 2009-2010 [19] . Besides, in the EURIKA study, conducted across many European countries, a large proportion of outpatients in primary prevention had cardiovascular risk factors that remained uncontrolled [20] . Overall, these results combine to suggest that hypercholesterolaemia often remains inadequately controlled, regardless of the country that is considered (France, Europe or the USA). In our study, approximately 10% of subjects with one associated risk factor, particularly those who were not receiving lipid-lowering therapy, did not reach the relatively conservative LDL-cholesterol target of less than 4.9 mmol/L (1.9 g/L) recommended in the French guidelines. This is a cause for concern, given that the French recommendations are less stringent than those of the ESC, and suggests that more intensive therapy is necessary to achieve even relatively high targets. Furthermore, most young subjects with LDL-cholesterol concentrations greater than 5.7 mmol/L (2.2 g/L) are likely to have familial hypercholesterolaemia; in this case an LDL-cholesterol target of 5.7 mmol/L (2.2 g/L) will maintain an elevated residual cardiovascular risk. In contrast, in the ESC guidelines, people with familial hypercholesterolaemia are considered to be at high risk, with a recommended LDL-cholesterol concentration of less than 2.6 mmol/L (1 g/L) [2, 3] .
In addition, a majority of participants with multiple risk factors, or those who were considered to be at high risk according to the French guidelines, did not reach their recommended targets. This might suggest that treatments given to these subjects were insufficient to reach the recommended goals and that more intensive lipid-lowering therapies are needed. However, it might also suggest that the level of risk in these subjects was not estimated accurately. The EURIKA study emphasizes that time constraints, lack of perceived usefulness and inadequate knowledge are barriers preventing physicians from using global risk assessment tools in primary prevention [21] . In accordance with this hypothesis, we found that the proportion of uncontrolled subjects was significantly lower in participants with documented cardiovascular disease (68.7%) than in high-risk primary prevention participants (87.1%), who may not have been identified as being at high risk by their general practitioner. In particular, people with a 10-year absolute risk of CHD greater than 20% may have not been recognized. One should, however, keep in mind that estimation of 10-year absolute risk of CHD with the Framingham equation tends to overestimate risk in the French population [22] .
An important result of our study is the reduction in LDLcholesterol required to meet target. With the exception of people identified as being at high risk by the French guidelines, a large majority of uncontrolled participants without treatment required reductions in LDL-cholesterol of less than 30% to reach the recommended targets. This means that a low dose of a generic statin would be adequate in most untreated primary prevention subjects, whereas statins with Table 3 Reductions in LDL-cholesterol required to meet targets recommended in French or ESC guidelines in subjects who were not receiving lipid-lowering therapy and did not reach their recommended LDL-cholesterol target.
Reduction required to meet target (%) Subjects requiring a given reduction to meet target a greater LDL-cholesterol-lowering effect might be more appropriate in high-risk patients requiring a larger reduction to meet the target or in patients in whom LDL-cholesterol remains uncontrolled despite treatment. One might be surprised by the discrepancies existing between French and European guidelines. The first difference is related to risk assessment, with the European definition of high and very high risk being much broader, including all diabetics, people with moderate chronic kidney disease and those with one markedly elevated single risk factor, whereas these situations are not categorized as high risk in the French guidelines. The second difference is related to the cholesterol goals, which are much more stringent in the European guidelines. For instance, the goal is 3 mmol/L (1.15 g/L) for the lowest risk group, while concentrations up to 3.4 mmol/L (1.30 g/L) are considered acceptable for people with three associated risk factors in the French guidelines. The consequence of these differences is that a larger proportion of candidates should receive a drug treatment when European guidelines are applied. Studies comparing, at the population level, the medical and the economic impact of these two strategies of risk assessment and risk management are sorely lacking. Such studies are obviously very complicated to conceive because of the multitude of confounding biases that have to be controlled. Two key questions are thus to be answered: do French criteria miss the identification of some high-risk subjects (e.g. those with familial hypercholesterolaemia), who consequently may be inappropriately managed?; and are European goals too stringent, leading to the excessive and unnecessary treatment of some low-risk subjects? Being demanding among low-risk subjects requires that affordable means can be proposed at the population level for lowering cholesterol. Besides, this should not distract practitioners from appropriately controlling high-risk subjects, a point that has to remain a priority.
Study limitations
Our study does have a number of limitations. It was conducted in three contrasting areas of France, rather than nationwide, and inclusion was restricted to subjects aged 35-74 years. Thus, the study population may not be truly representative of the general French population. Furthermore, the possibility of selection bias cannot be excluded. The participants had a relatively high average level of education and further bias could arise if sicker members of the population were unable to attend the hospital to participate in the study. It is therefore possible that the study population was healthier and better educated than the French general population. A further limitation of the study is that only one measurement of risk factors was made in each participant. Finally, some misclassification of the level of participants' cardiovascular risk may have arisen because familial hypercholesterolaemia and diabetes target organ damage were not recorded (microalbuminuria, neuropathy and retinopathy were missing). Besides, 10-year cardiovascular risk was estimated irrespective of the use of lipid-lowering drugs. Consequently, risk was underestimated in people with a long past history of elevated cholesterol without drug treatment and in those who stopped drug treatment after the present study.
Conclusions
In summary, this study has shown that, in a majority of primary prevention candidates with multiple risk factors and in most high-risk subjects, LDL-cholesterol targets recommended by the French guidelines are not being achieved in France. This might be attributed, in part, to the fact that high-risk subjects without documented cardiovascular disease may not be recognized as being at high risk. There is therefore a strong case for better screening of subjects with respect to their level of cardiovascular risk and for intensifying lipid-lowering therapy whenever necessary, with the aim of meeting the French guideline targets in the first instance. The study has also shown that the more stringent targets of the European guidelines are not being achieved in most cases.
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